#begin document (en_1691.txt); part 000
en_1691.txt	0	0	Cancer	NNP	(TOP(NP(NP*	-	-	-	-	*	-
en_1691.txt	0	1	'	POS	*)	-	-	-	-	*	-
en_1691.txt	0	2	s	JJ	*	-	-	-	-	*	-
en_1691.txt	0	3	Dangerous	JJ	*	-	-	-	-	*	-
en_1691.txt	0	4	Mythology	NN	*))	-	-	-	-	*	-

en_1691.txt	0	0	GENEVA	IN	(TOP(S(PP*	-	-	-	-	*	-
en_1691.txt	0	1	–	SYM	(NP(NP*)	-	-	-	-	*	(0
en_1691.txt	0	2	This	DT	(NP*	-	-	-	-	*	-
en_1691.txt	0	3	year	NN	*)))	-	-	-	-	*	0)
en_1691.txt	0	4	,	,	*	-	-	-	-	*	-
en_1691.txt	0	5	World	NNP	(NP*	-	-	-	-	*	(1
en_1691.txt	0	6	Cancer	NNP	*	-	-	-	-	*	-
en_1691.txt	0	7	Day	NNP	*)	-	-	-	-	*	1)
en_1691.txt	0	8	will	MD	(VP*	-	-	-	-	*	-
en_1691.txt	0	9	focus	VB	(VP*	-	-	-	-	*	-
en_1691.txt	0	10	on	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	11	dispelling	VBG	(S(VP*	-	-	-	-	*	-
en_1691.txt	0	12	damaging	JJ	(NP(NP*	-	-	-	-	*	-
en_1691.txt	0	13	myths	NNS	*)	-	-	-	-	*	-
en_1691.txt	0	14	about	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	15	the	DT	(NP*	-	-	-	-	*	(2
en_1691.txt	0	16	disease	NN	*))))))))	-	-	-	-	*	2)
en_1691.txt	0	17	.	.	*))	-	-	-	-	*	-

en_1691.txt	0	0	The	DT	(TOP(S(NP*	-	-	-	-	*	(0
en_1691.txt	0	1	theme	NN	*	-	-	-	-	*	-
en_1691.txt	0	2	–	NN	*)	-	-	-	-	*	0)
en_1691.txt	0	3	illustrated	VBD	(VP*	-	-	-	-	*	-
en_1691.txt	0	4	in	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	5	the	DT	(NP(UCP*	-	-	-	-	*	-
en_1691.txt	0	6	tagline	NN	*	-	-	-	-	*	-
en_1691.txt	0	7	``	``	*	-	-	-	-	*	-
en_1691.txt	0	8	Cancer	NN	*	-	-	-	-	*	-
en_1691.txt	0	9	–	SYM	(X*)	-	-	-	-	*	-
en_1691.txt	0	10	Did	VBD	(SQ*	-	-	-	-	*	-
en_1691.txt	0	11	you	PRP	(NP*)	-	-	-	-	*	-
en_1691.txt	0	12	know	VB	(VP*)	-	-	-	-	*	-
en_1691.txt	0	13	?	.	*)	-	-	-	-	*	-
en_1691.txt	0	14	''	''	*	-	-	-	-	*	-
en_1691.txt	0	15	–	SYM	(FRAG(X*)	-	-	-	-	*	-
en_1691.txt	0	16	offers	VBZ	(VP*	-	-	-	-	*	-
en_1691.txt	0	17	an	DT	(NP*	-	-	-	-	*	-
en_1691.txt	0	18	opportunity	NN	*	-	-	-	-	*	-
en_1691.txt	0	19	to	TO	(S(VP*	-	-	-	-	*	-
en_1691.txt	0	20	reflect	VB	(VP*	-	-	-	-	*	-
en_1691.txt	0	21	on	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	22	cancer	NN	(NP*)))))))	-	-	-	-	*	-
en_1691.txt	0	23	'	''	*)	-	-	-	-	*	-
en_1691.txt	0	24	s	VBZ	(VP(VP*	-	-	-	-	*	-
en_1691.txt	0	25	true	JJ	(NP*	-	-	-	-	*	-
en_1691.txt	0	26	consequences	NNS	*))	-	-	-	-	*	-
en_1691.txt	0	27	and	CC	*	-	-	-	-	*	-
en_1691.txt	0	28	enhance	VB	(VP*	-	-	-	-	*	-
en_1691.txt	0	29	global	JJ	(NP*	-	-	-	-	*	-
en_1691.txt	0	30	prevention	NN	*)))	-	-	-	-	*	-
en_1691.txt	0	31	and	CC	*	-	-	-	-	*	-
en_1691.txt	0	32	treatment	NN	*)	-	-	-	-	*	-
en_1691.txt	0	33	efforts	NNS	*)))	-	-	-	-	*	-
en_1691.txt	0	34	.	.	*))	-	-	-	-	*	-

en_1691.txt	0	0	One	CD	(TOP(S(NP*	-	-	-	-	*	(3
en_1691.txt	0	1	prevailing	JJ	*	-	-	-	-	*	-
en_1691.txt	0	2	myth	NN	*)	-	-	-	-	*	3)
en_1691.txt	0	3	is	VBZ	(VP*	-	-	-	-	*	-
en_1691.txt	0	4	that	IN	(SBAR*	-	-	-	-	*	-
en_1691.txt	0	5	cancer	NN	(S(NP*)	-	-	-	-	*	-
en_1691.txt	0	6	is	VBZ	(VP*	-	-	-	-	*	-
en_1691.txt	0	7	primarily	RB	(ADVP*)	-	-	-	-	*	-
en_1691.txt	0	8	a	DT	(NP*	-	-	-	-	*	-
en_1691.txt	0	9	developed-country	JJ	*	-	-	-	-	*	-
en_1691.txt	0	10	problem	NN	*)))))	-	-	-	-	*	-
en_1691.txt	0	11	.	.	*))	-	-	-	-	*	-

en_1691.txt	0	0	But	CC	(TOP(S*	-	-	-	-	*	-
en_1691.txt	0	1	,	,	*	-	-	-	-	*	-
en_1691.txt	0	2	while	IN	(SBAR*	-	-	-	-	*	-
en_1691.txt	0	3	it	PRP	(S(NP*)	-	-	-	-	*	(3)
en_1691.txt	0	4	is	VBZ	(VP*	-	-	-	-	*	-
en_1691.txt	0	5	true	JJ	(ADJP*)	-	-	-	-	*	-
en_1691.txt	0	6	that	IN	(SBAR*	-	-	-	-	*	-
en_1691.txt	0	7	cancer	NN	(S(NP*)	-	-	-	-	*	-
en_1691.txt	0	8	is	VBZ	(VP*	-	-	-	-	*	-
en_1691.txt	0	9	pervasive	JJ	(ADJP*	-	-	-	-	*	-
en_1691.txt	0	10	in	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	11	wealthy	JJ	(NP*	-	-	-	-	*	-
en_1691.txt	0	12	countries	NNS	*)))))))))	-	-	-	-	*	-
en_1691.txt	0	13	,	,	*	-	-	-	-	*	-
en_1691.txt	0	14	people	NNS	(NP(NP*)	-	-	-	-	*	-
en_1691.txt	0	15	in	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	16	the	DT	(NP(NP*	-	-	-	-	*	(4|(5
en_1691.txt	0	17	world	NN	*	-	-	-	-	*	-
en_1691.txt	0	18	'	POS	*)	-	-	-	-	*	4)
en_1691.txt	0	19	s	JJ	*	-	-	-	-	*	-
en_1691.txt	0	20	poorest	JJS	*	-	-	-	-	*	-
en_1691.txt	0	21	countries	NNS	*)))	-	-	-	-	*	5)
en_1691.txt	0	22	lose	VBP	(VP*	-	-	-	-	*	-
en_1691.txt	0	23	more	JJR	(NP*	-	-	-	-	*	-
en_1691.txt	0	24	years	NNS	*)	-	-	-	-	*	-
en_1691.txt	0	25	of	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	26	life	NN	(NP*))	-	-	-	-	*	-
en_1691.txt	0	27	to	TO	(PP*	-	-	-	-	*	-
en_1691.txt	0	28	the	DT	(NP*	-	-	-	-	*	(2
en_1691.txt	0	29	disease	NN	*)))	-	-	-	-	*	2)
en_1691.txt	0	30	.	.	*))	-	-	-	-	*	-

en_1691.txt	0	0	As	IN	(TOP(FRAG(X*	-	-	-	-	*	-
en_1691.txt	0	1	medical	JJ	(NP(NP*	-	-	-	-	*	-
en_1691.txt	0	2	advances	NNS	*)	-	-	-	-	*	-
en_1691.txt	0	3	and	CC	*	-	-	-	-	*	-
en_1691.txt	0	4	technological	JJ	(NP*	-	-	-	-	*	-
en_1691.txt	0	5	developments	NNS	*)))	-	-	-	-	*	-
en_1691.txt	0	6	have	VBP	(VP*	-	-	-	-	*	-
en_1691.txt	0	7	helped	VBN	(VP*	-	-	-	-	*	-
en_1691.txt	0	8	cancer	NN	(S(NP(NP*	-	-	-	-	*	-
en_1691.txt	0	9	patients	NNS	*)	-	-	-	-	*	-
en_1691.txt	0	10	in	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	11	high-income	JJ	(NP*	-	-	-	-	*	-
en_1691.txt	0	12	countries	NNS	*)))	-	-	-	-	*	-
en_1691.txt	0	13	to	TO	(VP*	-	-	-	-	*	-
en_1691.txt	0	14	live	VB	(VP*	-	-	-	-	*	-
en_1691.txt	0	15	longer	RB	(ADVP*))))))	-	-	-	-	*	-
en_1691.txt	0	16	–	SYM	(X*)	-	-	-	-	*	-
en_1691.txt	0	17	to	TO	(PP*	-	-	-	-	*	-
en_1691.txt	0	18	the	DT	(NP*	-	-	-	-	*	-
en_1691.txt	0	19	extent	NN	*	-	-	-	-	*	-
en_1691.txt	0	20	that	IN	(SBAR*	-	-	-	-	*	-
en_1691.txt	0	21	some	DT	(S(NP(NP*	-	-	-	-	*	-
en_1691.txt	0	22	forms	NNS	*)	-	-	-	-	*	-
en_1691.txt	0	23	of	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	24	cancer	NN	(NP*)))	-	-	-	-	*	-
en_1691.txt	0	25	have	VBP	(VP*	-	-	-	-	*	-
en_1691.txt	0	26	effectively	RB	(ADVP*)	-	-	-	-	*	-
en_1691.txt	0	27	become	VBN	(VP*	-	-	-	-	*	-
en_1691.txt	0	28	chronic	JJ	(NP*	-	-	-	-	*	-
en_1691.txt	0	29	conditions	NNS	*)))))))	-	-	-	-	*	-
en_1691.txt	0	30	–	SYM	(X*)	-	-	-	-	*	-
en_1691.txt	0	31	those	DT	(S(NP(NP*)	-	-	-	-	*	-
en_1691.txt	0	32	in	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	33	low-income	JJ	(NP*	-	-	-	-	*	-
en_1691.txt	0	34	countries	NNS	*)))	-	-	-	-	*	-
en_1691.txt	0	35	continue	VBP	(VP*	-	-	-	-	*	-
en_1691.txt	0	36	to	TO	(S(VP*	-	-	-	-	*	-
en_1691.txt	0	37	die	VB	(VP*	-	-	-	-	*	-
en_1691.txt	0	38	young	JJ	(NP*))))))	-	-	-	-	*	-
en_1691.txt	0	39	.	.	*))	-	-	-	-	*	-

en_1691.txt	0	0	Besides	IN	(TOP(S(PP*	-	-	-	-	*	-
en_1691.txt	0	1	being	VBG	(S(VP*	-	-	-	-	*	-
en_1691.txt	0	2	unjust	JJ	(ADJP*))))	-	-	-	-	*	-
en_1691.txt	0	3	,	,	*	-	-	-	-	*	-
en_1691.txt	0	4	this	DT	(NP*)	-	-	-	-	*	-
en_1691.txt	0	5	is	VBZ	(VP*	-	-	-	-	*	-
en_1691.txt	0	6	deeply	RB	(ADJP*	-	-	-	-	*	-
en_1691.txt	0	7	tragic	JJ	*))	-	-	-	-	*	-
en_1691.txt	0	8	.	.	*))	-	-	-	-	*	-

en_1691.txt	0	0	Having	VBG	(TOP(S(S(VP*	-	-	-	-	*	-
en_1691.txt	0	1	eluded	VBD	(NP(NP*	-	-	-	-	*	-
en_1691.txt	0	2	killers	NNS	*)	-	-	-	-	*	-
en_1691.txt	0	3	like	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	4	malaria	NNP	(NP(NP*)	-	-	-	-	*	-
en_1691.txt	0	5	and	CC	*	-	-	-	-	*	-
en_1691.txt	0	6	AIDS	NNP	(NP*))))))	-	-	-	-	*	-
en_1691.txt	0	7	,	,	*	-	-	-	-	*	-
en_1691.txt	0	8	one	NN	(NP*)	-	-	-	-	*	-
en_1691.txt	0	9	should	MD	(VP*	-	-	-	-	*	-
en_1691.txt	0	10	not	RB	*	-	-	-	-	*	-
en_1691.txt	0	11	then	RB	(ADVP*)	-	-	-	-	*	-
en_1691.txt	0	12	be	VB	(VP*	-	-	-	-	*	-
en_1691.txt	0	13	killed	VBN	(VP*	-	-	-	-	*	-
en_1691.txt	0	14	prematurely	RB	(ADVP*)	-	-	-	-	*	-
en_1691.txt	0	15	by	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	16	cancer	NN	(NP(NP*	-	-	-	-	*	-
en_1691.txt	0	17	–	NN	*)	-	-	-	-	*	-
en_1691.txt	0	18	especially	RB	(RRC(ADVP*)	-	-	-	-	*	-
en_1691.txt	0	19	a	DT	(NP(NP*	-	-	-	-	*	-
en_1691.txt	0	20	form	NN	*)	-	-	-	-	*	-
en_1691.txt	0	21	of	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	22	cancer	NN	(NP*))	-	-	-	-	*	-
en_1691.txt	0	23	that	WDT	(SBAR(WHNP*)	-	-	-	-	*	-
en_1691.txt	0	24	could	MD	(S(VP*	-	-	-	-	*	-
en_1691.txt	0	25	have	VB	(VP*	-	-	-	-	*	-
en_1691.txt	0	26	been	VBN	(VP*	-	-	-	-	*	-
en_1691.txt	0	27	prevented	VBN	(VP*	-	-	-	-	*	-
en_1691.txt	0	28	with	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	29	something	NN	(NP(NP*)	-	-	-	-	*	-
en_1691.txt	0	30	as	RB	(ADJP(ADJP*	-	-	-	-	*	-
en_1691.txt	0	31	simple	JJ	*)	-	-	-	-	*	-
en_1691.txt	0	32	and	CC	*	-	-	-	-	*	-
en_1691.txt	0	33	as	RB	(ADJP*	-	-	-	-	*	-
en_1691.txt	0	34	affordable	JJ	*))))))))))))))	-	-	-	-	*	-
en_1691.txt	0	35	as	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	36	a	DT	(NP*	-	-	-	-	*	-
en_1691.txt	0	37	vaccine	NN	*)))))	-	-	-	-	*	-
en_1691.txt	0	38	.	.	*))	-	-	-	-	*	-

en_1691.txt	0	0	The	DT	(TOP(S(S(NP(NP*	-	-	-	-	*	-
en_1691.txt	0	1	often-overlooked	JJ	*	-	-	-	-	*	-
en_1691.txt	0	2	link	NN	*)	-	-	-	-	*	-
en_1691.txt	0	3	between	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	4	vaccines	NNS	(NP(NP*)	-	-	-	-	*	-
en_1691.txt	0	5	and	CC	*	-	-	-	-	*	-
en_1691.txt	0	6	cancer	NN	(NP*))))	-	-	-	-	*	-
en_1691.txt	0	7	highlights	VBZ	(VP*	-	-	-	-	*	-
en_1691.txt	0	8	a	DT	(NP*	-	-	-	-	*	-
en_1691.txt	0	9	second	JJ	*	-	-	-	-	*	-
en_1691.txt	0	10	common	JJ	*	-	-	-	-	*	-
en_1691.txt	0	11	misconception	NN	*)))	-	-	-	-	*	-
en_1691.txt	0	12	:	:	*	-	-	-	-	*	-
en_1691.txt	0	13	fate	NN	(S(NP(NP*)	-	-	-	-	*	-
en_1691.txt	0	14	alone	RB	(ADVP*)	-	-	-	-	*	-
en_1691.txt	0	15	-LRB-	-LRB-	(PRN*	-	-	-	-	*	-
en_1691.txt	0	16	and	CC	*	-	-	-	-	*	-
en_1691.txt	0	17	perhaps	RB	(NP*	-	-	-	-	*	-
en_1691.txt	0	18	smoking	NN	*)	-	-	-	-	*	-
en_1691.txt	0	19	-RRB-	-RRB-	*))	-	-	-	-	*	-
en_1691.txt	0	20	determines	VBZ	(VP*	-	-	-	-	*	-
en_1691.txt	0	21	who	WP	(SBAR(WHNP*)	-	-	-	-	*	-
en_1691.txt	0	22	gets	VBZ	(S(VP*	-	-	-	-	*	-
en_1691.txt	0	23	cancer	NN	(NP*))))))	-	-	-	-	*	-
en_1691.txt	0	24	.	.	*))	-	-	-	-	*	-

en_1691.txt	0	0	In	IN	(TOP(S(PP*	-	-	-	-	*	-
en_1691.txt	0	1	fact	NN	(NP*))	-	-	-	-	*	-
en_1691.txt	0	2	,	,	*	-	-	-	-	*	-
en_1691.txt	0	3	one	CD	(NP(NP*)	-	-	-	-	*	-
en_1691.txt	0	4	in	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	5	six	CD	(NP*	-	-	-	-	*	-
en_1691.txt	0	6	cancer	NN	*	-	-	-	-	*	-
en_1691.txt	0	7	cases	NNS	*)))	-	-	-	-	*	-
en_1691.txt	0	8	worldwide	RB	(ADVP*)	-	-	-	-	*	-
en_1691.txt	0	9	is	VBZ	(VP*	-	-	-	-	*	-
en_1691.txt	0	10	caused	VBN	(VP*	-	-	-	-	*	-
en_1691.txt	0	11	by	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	12	a	DT	(NP*	-	-	-	-	*	-
en_1691.txt	0	13	known	VBN	*	-	-	-	-	*	-
en_1691.txt	0	14	infectious	JJ	*	-	-	-	-	*	-
en_1691.txt	0	15	agent	NN	*))	-	-	-	-	*	-
en_1691.txt	0	16	,	,	*	-	-	-	-	*	-
en_1691.txt	0	17	with	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	18	the	DT	(S(NP*	-	-	-	-	*	-
en_1691.txt	0	19	proportion	NN	*)	-	-	-	-	*	-
en_1691.txt	0	20	rising	VBG	(VP*	-	-	-	-	*	-
en_1691.txt	0	21	to	TO	(PP*	-	-	-	-	*	-
en_1691.txt	0	22	one-third	JJ	(NP*))	-	-	-	-	*	-
en_1691.txt	0	23	in	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	24	some	DT	(NP(NP*	-	-	-	-	*	-
en_1691.txt	0	25	countries	NNS	*)	-	-	-	-	*	-
en_1691.txt	0	26	in	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	27	Sub-Saharan	NNP	(NP*	-	-	-	-	*	-
en_1691.txt	0	28	Africa	NNP	*)))))))))	-	-	-	-	*	-
en_1691.txt	0	29	.	.	*))	-	-	-	-	*	-

en_1691.txt	0	0	The	DT	(TOP(S(NP*	-	-	-	-	*	-
en_1691.txt	0	1	four	CD	*	-	-	-	-	*	-
en_1691.txt	0	2	main	JJ	*	-	-	-	-	*	-
en_1691.txt	0	3	culprits	NNS	*)	-	-	-	-	*	-
en_1691.txt	0	4	are	VBP	(VP*	-	-	-	-	*	-
en_1691.txt	0	5	hepatitis	NNP	(NP(NP(NP(NP(NP(NP*	-	-	-	-	*	-
en_1691.txt	0	6	B	NNP	*)	-	-	-	-	*	-
en_1691.txt	0	7	and	CC	*	-	-	-	-	*	-
en_1691.txt	0	8	C	NNP	*)	-	-	-	-	*	-
en_1691.txt	0	9	-LRB-	-LRB-	(PRN*	-	-	-	-	*	-
en_1691.txt	0	10	hepB	NN	(NP*	-	-	-	-	*	-
en_1691.txt	0	11	and	CC	*	-	-	-	-	*	-
en_1691.txt	0	12	hepC	NN	*)	-	-	-	-	*	-
en_1691.txt	0	13	-RRB-	-RRB-	*))	-	-	-	-	*	-
en_1691.txt	0	14	,	,	*	-	-	-	-	*	-
en_1691.txt	0	15	human	JJ	(NP*	-	-	-	-	*	-
en_1691.txt	0	16	papillomavirus	NN	*))	-	-	-	-	*	-
en_1691.txt	0	17	-LRB-	-LRB-	(PRN*	-	-	-	-	*	-
en_1691.txt	0	18	HPV	NNP	(NP*)	-	-	-	-	*	(6)
en_1691.txt	0	19	-RRB-	-RRB-	*))	-	-	-	-	*	-
en_1691.txt	0	20	,	,	*	-	-	-	-	*	-
en_1691.txt	0	21	and	CC	*	-	-	-	-	*	-
en_1691.txt	0	22	Helicobacter	NNP	(NP(NP*	-	-	-	-	*	-
en_1691.txt	0	23	pylori	NN	*)	-	-	-	-	*	-
en_1691.txt	0	24	,	,	*	-	-	-	-	*	-
en_1691.txt	0	25	which	WDT	(SBAR(WHNP*)	-	-	-	-	*	-
en_1691.txt	0	26	are	VBP	(S(VP*	-	-	-	-	*	-
en_1691.txt	0	27	collectively	RB	(ADVP*)	-	-	-	-	*	-
en_1691.txt	0	28	responsible	JJ	(ADJP*	-	-	-	-	*	-
en_1691.txt	0	29	for	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	30	1.9	CD	(NP(NP(QP*	-	-	-	-	*	-
en_1691.txt	0	31	million	CD	*)	-	-	-	-	*	-
en_1691.txt	0	32	cases	NNS	*)	-	-	-	-	*	-
en_1691.txt	0	33	of	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	34	liver	NN	(NP(NP*)	-	-	-	-	*	-
en_1691.txt	0	35	,	,	*	-	-	-	-	*	-
en_1691.txt	0	36	cervical	NNS	(NP*)	-	-	-	-	*	-
en_1691.txt	0	37	,	,	*	-	-	-	-	*	-
en_1691.txt	0	38	and	CC	*	-	-	-	-	*	-
en_1691.txt	0	39	gastric	JJ	(NP*	-	-	-	-	*	-
en_1691.txt	0	40	cancer	NN	*))))))	-	-	-	-	*	-
en_1691.txt	0	41	annually	RB	(ADVP*)))))))	-	-	-	-	*	-
en_1691.txt	0	42	.	.	*))	-	-	-	-	*	-

en_1691.txt	0	0	Cervical	JJ	(TOP(S(NP*	-	-	-	-	*	-
en_1691.txt	0	1	cancer	NN	*)	-	-	-	-	*	-
en_1691.txt	0	2	now	RB	(ADVP*)	-	-	-	-	*	-
en_1691.txt	0	3	kills	VBZ	(VP*	-	-	-	-	*	-
en_1691.txt	0	4	more	JJR	(NP(NP*	-	-	-	-	*	-
en_1691.txt	0	5	women	NNS	*)	-	-	-	-	*	-
en_1691.txt	0	6	than	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	7	childbirth	JJ	(ADJP*)))	-	-	-	-	*	-
en_1691.txt	0	8	,	,	*	-	-	-	-	*	-
en_1691.txt	0	9	claiming	VBG	(S(VP*	-	-	-	-	*	-
en_1691.txt	0	10	a	DT	(NP*	-	-	-	-	*	-
en_1691.txt	0	11	life	NN	*)	-	-	-	-	*	-
en_1691.txt	0	12	every	DT	(NP*	-	-	-	-	*	-
en_1691.txt	0	13	two	CD	*	-	-	-	-	*	-
en_1691.txt	0	14	minutes	NNS	*))))	-	-	-	-	*	-
en_1691.txt	0	15	.	.	*))	-	-	-	-	*	-

en_1691.txt	0	0	Of	IN	(TOP(S(PP*	-	-	-	-	*	-
en_1691.txt	0	1	the	DT	(NP(NP*	-	-	-	-	*	-
en_1691.txt	0	2	275,000	CD	*	-	-	-	-	*	-
en_1691.txt	0	3	women	NNS	*)	-	-	-	-	*	-
en_1691.txt	0	4	who	WP	(SBAR(WHNP*)	-	-	-	-	*	-
en_1691.txt	0	5	die	VBP	(S(VP*	-	-	-	-	*	-
en_1691.txt	0	6	of	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	7	cervical	JJ	(NP(NP*	-	-	-	-	*	-
en_1691.txt	0	8	cancer	NN	*)	-	-	-	-	*	-
en_1691.txt	0	9	annually	RB	(ADVP*))))))))	-	-	-	-	*	-
en_1691.txt	0	10	,	,	*	-	-	-	-	*	-
en_1691.txt	0	11	85	CD	(NP*	-	-	-	-	*	-
en_1691.txt	0	12	%	NN	*)	-	-	-	-	*	-
en_1691.txt	0	13	live	VBP	(VP*	-	-	-	-	*	-
en_1691.txt	0	14	in	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	15	the	DT	(NP(NP*	-	-	-	-	*	(4|(5
en_1691.txt	0	16	world	NN	*	-	-	-	-	*	-
en_1691.txt	0	17	'	POS	*)	-	-	-	-	*	4)
en_1691.txt	0	18	s	JJ	*	-	-	-	-	*	-
en_1691.txt	0	19	poorest	JJS	*	-	-	-	-	*	-
en_1691.txt	0	20	countries	NNS	*)))	-	-	-	-	*	5)
en_1691.txt	0	21	.	.	*))	-	-	-	-	*	-

en_1691.txt	0	0	After	IN	(TOP(S(PP*	-	-	-	-	*	-
en_1691.txt	0	1	all	DT	(NP*))	-	-	-	-	*	-
en_1691.txt	0	2	,	,	*	-	-	-	-	*	-
en_1691.txt	0	3	cervical	JJ	(NP*	-	-	-	-	*	-
en_1691.txt	0	4	cancer	NN	*)	-	-	-	-	*	-
en_1691.txt	0	5	tends	VBZ	(VP*	-	-	-	-	*	-
en_1691.txt	0	6	to	TO	(S(VP*	-	-	-	-	*	-
en_1691.txt	0	7	target	VB	(VP*	-	-	-	-	*	-
en_1691.txt	0	8	the	DT	(NP(NP*	-	-	-	-	*	-
en_1691.txt	0	9	most	RBS	(ADJP*	-	-	-	-	*	-
en_1691.txt	0	10	vulnerable	JJ	*))	-	-	-	-	*	-
en_1691.txt	0	11	in	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	12	particular	NN	(NP*)))	-	-	-	-	*	-
en_1691.txt	0	13	,	,	*	-	-	-	-	*	-
en_1691.txt	0	14	such	JJ	(PP*	-	-	-	-	*	-
en_1691.txt	0	15	as	IN	*	-	-	-	-	*	-
en_1691.txt	0	16	women	NNS	(NP(NP*)	-	-	-	-	*	-
en_1691.txt	0	17	infected	VBN	(VP*	-	-	-	-	*	-
en_1691.txt	0	18	with	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	19	HIV	NNP	(NP*)))))))))	-	-	-	-	*	(7)
en_1691.txt	0	20	.	.	*))	-	-	-	-	*	-

en_1691.txt	0	0	If	IN	(TOP(S(SBAR*	-	-	-	-	*	-
en_1691.txt	0	1	left	VBN	(S(VP*	-	-	-	-	*	-
en_1691.txt	0	2	unchecked	JJ	(S(ADJP*)))))	-	-	-	-	*	-
en_1691.txt	0	3	,	,	*	-	-	-	-	*	-
en_1691.txt	0	4	the	DT	(NP(NP*	-	-	-	-	*	-
en_1691.txt	0	5	number	NN	*)	-	-	-	-	*	-
en_1691.txt	0	6	of	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	7	cervical	JJ	(NP*	-	-	-	-	*	(8
en_1691.txt	0	8	cancer	NN	*	-	-	-	-	*	-
en_1691.txt	0	9	deaths	NNS	*)))	-	-	-	-	*	8)
en_1691.txt	0	10	is	VBZ	(VP*	-	-	-	-	*	-
en_1691.txt	0	11	set	VBN	(VP*	-	-	-	-	*	-
en_1691.txt	0	12	to	TO	(S(VP*	-	-	-	-	*	-
en_1691.txt	0	13	rise	VB	(VP*	-	-	-	-	*	-
en_1691.txt	0	14	to	TO	(PP*	-	-	-	-	*	-
en_1691.txt	0	15	430,000	CD	(NP*))	-	-	-	-	*	-
en_1691.txt	0	16	annually	RB	(ADVP*)	-	-	-	-	*	-
en_1691.txt	0	17	by	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	18	2030	CD	(NP*)))))))	-	-	-	-	*	-
en_1691.txt	0	19	.	.	*))	-	-	-	-	*	-

en_1691.txt	0	0	Then	RB	(TOP(S(ADVP*)	-	-	-	-	*	-
en_1691.txt	0	1	there	EX	(NP*)	-	-	-	-	*	-
en_1691.txt	0	2	is	VBZ	(VP*	-	-	-	-	*	-
en_1691.txt	0	3	hepB	JJ	(ADJP*)	-	-	-	-	*	-
en_1691.txt	0	4	,	,	*	-	-	-	-	*	-
en_1691.txt	0	5	which	WDT	(SBAR(WHNP*)	-	-	-	-	*	-
en_1691.txt	0	6	is	VBZ	(S(VP*	-	-	-	-	*	-
en_1691.txt	0	7	over	IN	(ADJP(ADJP(ADJP(QP*	-	-	-	-	*	-
en_1691.txt	0	8	50	CD	*	-	-	-	-	*	-
en_1691.txt	0	9	times	NNS	*)	-	-	-	-	*	-
en_1691.txt	0	10	more	RBR	*	-	-	-	-	*	-
en_1691.txt	0	11	infectious	JJ	*)	-	-	-	-	*	-
en_1691.txt	0	12	than	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	13	HIV	NNP	(NP*)))	-	-	-	-	*	(7)
en_1691.txt	0	14	and	CC	*	-	-	-	-	*	-
en_1691.txt	0	15	often	RB	(ADJP*	-	-	-	-	*	-
en_1691.txt	0	16	passed	VBN	*	-	-	-	-	*	-
en_1691.txt	0	17	from	IN	(PP(PP*	-	-	-	-	*	-
en_1691.txt	0	18	mother	NN	(NP*))	-	-	-	-	*	-
en_1691.txt	0	19	to	TO	(PP*	-	-	-	-	*	-
en_1691.txt	0	20	child	NN	(NP(NP*)	-	-	-	-	*	-
en_1691.txt	0	21	before	RB	(UCP(ADVP*)	-	-	-	-	*	-
en_1691.txt	0	22	or	CC	*	-	-	-	-	*	-
en_1691.txt	0	23	shortly	RB	(PP(ADVP*)	-	-	-	-	*	-
en_1691.txt	0	24	after	IN	*	-	-	-	-	*	-
en_1691.txt	0	25	birth	NN	(NP*)))))))))))	-	-	-	-	*	-
en_1691.txt	0	26	,	,	*	-	-	-	-	*	-
en_1691.txt	0	27	increasing	VBG	(S(VP*	-	-	-	-	*	-
en_1691.txt	0	28	the	DT	(NP(NP*	-	-	-	-	*	-
en_1691.txt	0	29	likelihood	NN	*)	-	-	-	-	*	-
en_1691.txt	0	30	of	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	31	liver	NN	(NP*	-	-	-	-	*	-
en_1691.txt	0	32	cancer	NN	*)))	-	-	-	-	*	-
en_1691.txt	0	33	later	RB	(ADVP*	-	-	-	-	*	-
en_1691.txt	0	34	in	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	35	life	NN	(NP*))))))	-	-	-	-	*	-
en_1691.txt	0	36	.	.	*))	-	-	-	-	*	-

en_1691.txt	0	0	An	DT	(TOP(S(NP*	-	-	-	-	*	-
en_1691.txt	0	1	estimated	VBN	*	-	-	-	-	*	-
en_1691.txt	0	2	two	CD	(ADJP(QP*	-	-	-	-	*	-
en_1691.txt	0	3	billion	CD	*)	-	-	-	-	*	-
en_1691.txt	0	4	people	NNS	*)	-	-	-	-	*	-
en_1691.txt	0	5	alive	JJ	*	-	-	-	-	*	-
en_1691.txt	0	6	today	NN	*)	-	-	-	-	*	-
en_1691.txt	0	7	have	VBP	(VP*	-	-	-	-	*	-
en_1691.txt	0	8	been	VBN	(VP*	-	-	-	-	*	-
en_1691.txt	0	9	infected	VBN	(VP*	-	-	-	-	*	-
en_1691.txt	0	10	with	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	11	hepB	NN	(NP*))	-	-	-	-	*	-
en_1691.txt	0	12	,	,	*	-	-	-	-	*	-
en_1691.txt	0	13	while	IN	(SBAR*	-	-	-	-	*	-
en_1691.txt	0	14	350	CD	(S(NP*	-	-	-	-	*	(9
en_1691.txt	0	15	million	CD	*	-	-	-	-	*	-
en_1691.txt	0	16	people	NNS	*)	-	-	-	-	*	9)
en_1691.txt	0	17	are	VBP	(VP*	-	-	-	-	*	-
en_1691.txt	0	18	chronically	RB	(VP(ADVP*)	-	-	-	-	*	-
en_1691.txt	0	19	infected	VBN	*)))))))	-	-	-	-	*	-
en_1691.txt	0	20	.	.	*))	-	-	-	-	*	-

en_1691.txt	0	0	Of	IN	(TOP(S(PP*	-	-	-	-	*	-
en_1691.txt	0	1	these	DT	(NP*))	-	-	-	-	*	(9)
en_1691.txt	0	2	,	,	*	-	-	-	-	*	-
en_1691.txt	0	3	roughly	RB	(NP*	-	-	-	-	*	-
en_1691.txt	0	4	one-quarter	NN	*)	-	-	-	-	*	-
en_1691.txt	0	5	will	MD	(VP*	-	-	-	-	*	-
en_1691.txt	0	6	die	VB	(VP*	-	-	-	-	*	-
en_1691.txt	0	7	from	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	8	hepB-related	JJ	(NP*	-	-	-	-	*	-
en_1691.txt	0	9	liver	NN	(NX(NX*	-	-	-	-	*	-
en_1691.txt	0	10	cancer	NN	*)	-	-	-	-	*	-
en_1691.txt	0	11	or	CC	*	-	-	-	-	*	-
en_1691.txt	0	12	cirrhosis	NN	(NX(NX*)	-	-	-	-	*	-
en_1691.txt	0	13	-LRB-	-LRB-	(PRN*	-	-	-	-	*	-
en_1691.txt	0	14	a	DT	(NP(NP*	-	-	-	-	*	-
en_1691.txt	0	15	consequence	NN	*)	-	-	-	-	*	-
en_1691.txt	0	16	of	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	17	chronic	JJ	(NP*	-	-	-	-	*	-
en_1691.txt	0	18	liver	NN	*	-	-	-	-	*	-
en_1691.txt	0	19	disease	NN	*)))	-	-	-	-	*	-
en_1691.txt	0	20	-RRB-	-RRB-	*)))))))	-	-	-	-	*	-
en_1691.txt	0	21	.	.	*))	-	-	-	-	*	-

en_1691.txt	0	0	The	DT	(TOP(S(NP*	-	-	-	-	*	-
en_1691.txt	0	1	good	JJ	*	-	-	-	-	*	-
en_1691.txt	0	2	news	NN	*)	-	-	-	-	*	-
en_1691.txt	0	3	is	VBZ	(VP*	-	-	-	-	*	-
en_1691.txt	0	4	that	IN	(SBAR*	-	-	-	-	*	-
en_1691.txt	0	5	powerful	JJ	(S(NP*	-	-	-	-	*	-
en_1691.txt	0	6	tools	NNS	*)	-	-	-	-	*	-
en_1691.txt	0	7	are	VBP	(VP*	-	-	-	-	*	-
en_1691.txt	0	8	available	JJ	(ADJP*	-	-	-	-	*	-
en_1691.txt	0	9	to	TO	(S(VP*	-	-	-	-	*	-
en_1691.txt	0	10	avert	VB	(VP*	-	-	-	-	*	-
en_1691.txt	0	11	many	JJ	(NP(NP*)	-	-	-	-	*	-
en_1691.txt	0	12	of	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	13	these	DT	(NP*	-	-	-	-	*	(8
en_1691.txt	0	14	deaths	NNS	*)))))))))))	-	-	-	-	*	8)
en_1691.txt	0	15	.	.	*))	-	-	-	-	*	-

en_1691.txt	0	0	Existing	VBG	(TOP(S(S(NP*	-	-	-	-	*	(10
en_1691.txt	0	1	HPV	NNP	*	-	-	-	-	*	-
en_1691.txt	0	2	vaccines	NNS	*)	-	-	-	-	*	10)
en_1691.txt	0	3	can	MD	(VP*	-	-	-	-	*	-
en_1691.txt	0	4	prevent	VB	(VP*	-	-	-	-	*	-
en_1691.txt	0	5	up	IN	(NP(NP(QP*	-	-	-	-	*	-
en_1691.txt	0	6	to	TO	*	-	-	-	-	*	-
en_1691.txt	0	7	70	CD	*)	-	-	-	-	*	-
en_1691.txt	0	8	%	NN	*)	-	-	-	-	*	-
en_1691.txt	0	9	of	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	10	cervical	JJ	(NP*	-	-	-	-	*	-
en_1691.txt	0	11	cancer	NN	*	-	-	-	-	*	-
en_1691.txt	0	12	cases	NNS	*))))))	-	-	-	-	*	-
en_1691.txt	0	13	,	,	*	-	-	-	-	*	-
en_1691.txt	0	14	and	CC	*	-	-	-	-	*	-
en_1691.txt	0	15	new	JJ	(S(NP*	-	-	-	-	*	-
en_1691.txt	0	16	vaccines	NNS	*)	-	-	-	-	*	-
en_1691.txt	0	17	are	VBP	(VP*	-	-	-	-	*	-
en_1691.txt	0	18	in	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	19	the	DT	(NP(NP*	-	-	-	-	*	-
en_1691.txt	0	20	pipeline	NN	*)	-	-	-	-	*	-
en_1691.txt	0	21	that	WDT	(SBAR(WHNP*)	-	-	-	-	*	-
en_1691.txt	0	22	will	MD	(S(VP*	-	-	-	-	*	-
en_1691.txt	0	23	improve	VB	(VP*	-	-	-	-	*	-
en_1691.txt	0	24	this	DT	(NP(NP*	-	-	-	-	*	-
en_1691.txt	0	25	record	NN	*)	-	-	-	-	*	-
en_1691.txt	0	26	further	RB	(ADVP*))))))))))	-	-	-	-	*	-
en_1691.txt	0	27	.	.	*))	-	-	-	-	*	-

en_1691.txt	0	0	Likewise	RB	(TOP(S(ADVP*)	-	-	-	-	*	-
en_1691.txt	0	1	,	,	*	-	-	-	-	*	-
en_1691.txt	0	2	hepB	NN	(NP*	-	-	-	-	*	-
en_1691.txt	0	3	vaccines	NNS	*)	-	-	-	-	*	-
en_1691.txt	0	4	are	VBP	(VP*	-	-	-	-	*	-
en_1691.txt	0	5	95	CD	(ADJP(NP*	-	-	-	-	*	-
en_1691.txt	0	6	%	NN	*)	-	-	-	-	*	-
en_1691.txt	0	7	effective	JJ	*	-	-	-	-	*	-
en_1691.txt	0	8	at	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	9	preventing	VBG	(S(VP*	-	-	-	-	*	-
en_1691.txt	0	10	infection	NN	(NP(NP*)	-	-	-	-	*	(11)
en_1691.txt	0	11	and	CC	*	-	-	-	-	*	-
en_1691.txt	0	12	its	PRP$	(NP*	-	-	-	-	*	(11)
en_1691.txt	0	13	chronic	JJ	*	-	-	-	-	*	-
en_1691.txt	0	14	consequences	NNS	*)))))))	-	-	-	-	*	-
en_1691.txt	0	15	.	.	*))	-	-	-	-	*	-

en_1691.txt	0	0	Vaccines	NNS	(TOP(S(S(NP(NP*)	-	-	-	-	*	-
en_1691.txt	0	1	protecting	VBG	(VP*	-	-	-	-	*	-
en_1691.txt	0	2	against	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	3	Helicobacter	NNP	(NP*	-	-	-	-	*	-
en_1691.txt	0	4	pylori	NN	*	-	-	-	-	*	-
en_1691.txt	0	5	and	CC	*	-	-	-	-	*	-
en_1691.txt	0	6	hepC	NN	*))))	-	-	-	-	*	-
en_1691.txt	0	7	are	VBP	(VP*	-	-	-	-	*	-
en_1691.txt	0	8	in	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	9	development	NN	(NP*))))	-	-	-	-	*	-
en_1691.txt	0	10	-LRB-	-LRB-	(PRN*	-	-	-	-	*	-
en_1691.txt	0	11	although	IN	(SBAR*	-	-	-	-	*	-
en_1691.txt	0	12	the	DT	(S(NP*	-	-	-	-	*	-
en_1691.txt	0	13	latter	NN	*)	-	-	-	-	*	-
en_1691.txt	0	14	is	VBZ	(VP*	-	-	-	-	*	-
en_1691.txt	0	15	proving	VBG	(VP*	-	-	-	-	*	-
en_1691.txt	0	16	particularly	RB	(ADJP*	-	-	-	-	*	-
en_1691.txt	0	17	challenging	JJ	*)))))	-	-	-	-	*	-
en_1691.txt	0	18	-RRB-	-RRB-	*)	-	-	-	-	*	-
en_1691.txt	0	19	.	.	*))	-	-	-	-	*	-

en_1691.txt	0	0	Even	RB	(TOP(S(NP(NP*	-	-	-	-	*	-
en_1691.txt	0	1	an	DT	*	-	-	-	-	*	-
en_1691.txt	0	2	Epstein-Barr	JJ	*	-	-	-	-	*	-
en_1691.txt	0	3	virus	NN	*	-	-	-	-	*	-
en_1691.txt	0	4	vaccine	NN	*)	-	-	-	-	*	-
en_1691.txt	0	5	,	,	*	-	-	-	-	*	-
en_1691.txt	0	6	which	WDT	(SBAR(WHNP*)	-	-	-	-	*	-
en_1691.txt	0	7	would	MD	(S(VP*	-	-	-	-	*	-
en_1691.txt	0	8	protect	VB	(VP*	-	-	-	-	*	-
en_1691.txt	0	9	against	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	10	some	DT	(NP(NP*	-	-	-	-	*	-
en_1691.txt	0	11	kinds	NNS	*)	-	-	-	-	*	-
en_1691.txt	0	12	of	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	13	lymphoma	NN	(NP*))))))))	-	-	-	-	*	-
en_1691.txt	0	14	,	,	*)	-	-	-	-	*	-
en_1691.txt	0	15	is	VBZ	(VP*	-	-	-	-	*	-
en_1691.txt	0	16	achieving	VBG	(VP*	-	-	-	-	*	-
en_1691.txt	0	17	promising	JJ	(NP*	-	-	-	-	*	-
en_1691.txt	0	18	results	NNS	*)))	-	-	-	-	*	-
en_1691.txt	0	19	.	.	*))	-	-	-	-	*	-

en_1691.txt	0	0	But	CC	(TOP(S*	-	-	-	-	*	-
en_1691.txt	0	1	paying	VBG	(S(VP(VP*	-	-	-	-	*	-
en_1691.txt	0	2	for	IN	(PP*))	-	-	-	-	*	-
en_1691.txt	0	3	and	CC	*	-	-	-	-	*	-
en_1691.txt	0	4	delivering	VBG	(VP*	-	-	-	-	*	-
en_1691.txt	0	5	these	DT	(NP*	-	-	-	-	*	(10
en_1691.txt	0	6	vaccines	NNS	*)	-	-	-	-	*	10)
en_1691.txt	0	7	to	TO	(PP*	-	-	-	-	*	-
en_1691.txt	0	8	the	DT	(NP(NP*	-	-	-	-	*	-
en_1691.txt	0	9	most	RBS	(ADJP*	-	-	-	-	*	-
en_1691.txt	0	10	vulnerable	JJ	*)	-	-	-	-	*	-
en_1691.txt	0	11	citizens	NNS	*)	-	-	-	-	*	-
en_1691.txt	0	12	of	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	13	low-income	JJ	(NP*	-	-	-	-	*	-
en_1691.txt	0	14	countries	NNS	*)))))))	-	-	-	-	*	-
en_1691.txt	0	15	poses	VBZ	(VP*	-	-	-	-	*	-
en_1691.txt	0	16	a	DT	(NP*	-	-	-	-	*	-
en_1691.txt	0	17	significant	JJ	*	-	-	-	-	*	-
en_1691.txt	0	18	challenge	NN	*))	-	-	-	-	*	-
en_1691.txt	0	19	.	.	*))	-	-	-	-	*	-

en_1691.txt	0	0	Although	IN	(TOP(S(SBAR*	-	-	-	-	*	-
en_1691.txt	0	1	the	DT	(S(NP(NP*	-	-	-	-	*	(12
en_1691.txt	0	2	World	NNP	*	-	-	-	-	*	-
en_1691.txt	0	3	Health	NNP	*	-	-	-	-	*	-
en_1691.txt	0	4	Organization	NNP	*)	-	-	-	-	*	-
en_1691.txt	0	5	-LRB-	-LRB-	(PRN*	-	-	-	-	*	-
en_1691.txt	0	6	WHO	NNP	(NP*)	-	-	-	-	*	-
en_1691.txt	0	7	-RRB-	-RRB-	*))	-	-	-	-	*	12)
en_1691.txt	0	8	has	VBZ	(VP*	-	-	-	-	*	-
en_1691.txt	0	9	recommended	VBN	(VP*	-	-	-	-	*	-
en_1691.txt	0	10	including	VBG	(PP*	-	-	-	-	*	-
en_1691.txt	0	11	the	DT	(NP(NP*	-	-	-	-	*	-
en_1691.txt	0	12	hepB	JJ	*	-	-	-	-	*	-
en_1691.txt	0	13	vaccine	NN	*)	-	-	-	-	*	-
en_1691.txt	0	14	in	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	15	routine	JJ	(NP*	-	-	-	-	*	-
en_1691.txt	0	16	immunization	NN	*))	-	-	-	-	*	-
en_1691.txt	0	17	since	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	18	1992	CD	(NP*))))))))	-	-	-	-	*	-
en_1691.txt	0	19	,	,	*	-	-	-	-	*	-
en_1691.txt	0	20	its	PRP$	(NP*	-	-	-	-	*	(12)
en_1691.txt	0	21	high	JJ	*	-	-	-	-	*	-
en_1691.txt	0	22	price	NN	*)	-	-	-	-	*	-
en_1691.txt	0	23	initially	RB	(ADVP*)	-	-	-	-	*	-
en_1691.txt	0	24	hindered	VBD	(VP*	-	-	-	-	*	-
en_1691.txt	0	25	its	PRP$	(NP*	-	-	-	-	*	(12)
en_1691.txt	0	26	uptake	NN	*)	-	-	-	-	*	-
en_1691.txt	0	27	in	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	28	some	DT	(NP*	-	-	-	-	*	-
en_1691.txt	0	29	developing	VBG	*	-	-	-	-	*	-
en_1691.txt	0	30	countries	NNS	*)))	-	-	-	-	*	-
en_1691.txt	0	31	.	.	*))	-	-	-	-	*	-

en_1691.txt	0	0	More	RBR	(TOP(S(ADVP*	-	-	-	-	*	-
en_1691.txt	0	1	recently	RB	*)	-	-	-	-	*	-
en_1691.txt	0	2	,	,	*	-	-	-	-	*	-
en_1691.txt	0	3	the	DT	(NP*	-	-	-	-	*	-
en_1691.txt	0	4	same	JJ	*	-	-	-	-	*	-
en_1691.txt	0	5	problem	NN	*)	-	-	-	-	*	-
en_1691.txt	0	6	threatened	VBD	(VP*	-	-	-	-	*	-
en_1691.txt	0	7	to	TO	(S(VP*	-	-	-	-	*	-
en_1691.txt	0	8	hinder	VB	(VP*	-	-	-	-	*	-
en_1691.txt	0	9	the	DT	(NP(NP*	-	-	-	-	*	-
en_1691.txt	0	10	adoption	NN	*)	-	-	-	-	*	-
en_1691.txt	0	11	of	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	12	HPV	NNP	(NP*	-	-	-	-	*	-
en_1691.txt	0	13	vaccines	NNS	*)))))))	-	-	-	-	*	-
en_1691.txt	0	14	.	.	*))	-	-	-	-	*	-

en_1691.txt	0	0	But	CC	(TOP(S*	-	-	-	-	*	-
en_1691.txt	0	1	the	DT	(S(NP*	-	-	-	-	*	(13
en_1691.txt	0	2	GAVI	NNP	*	-	-	-	-	*	-
en_1691.txt	0	3	Alliance	NNP	*)	-	-	-	-	*	13)
en_1691.txt	0	4	intervened	VBD	(VP*	-	-	-	-	*	-
en_1691.txt	0	5	to	TO	(S(VP*	-	-	-	-	*	-
en_1691.txt	0	6	ensure	VB	(VP*	-	-	-	-	*	-
en_1691.txt	0	7	that	IN	(SBAR*	-	-	-	-	*	-
en_1691.txt	0	8	this	DT	(S(NP*)	-	-	-	-	*	(14)
en_1691.txt	0	9	is	VBZ	(VP*	-	-	-	-	*	-
en_1691.txt	0	10	no	RB	(ADVP*	-	-	-	-	*	-
en_1691.txt	0	11	longer	RB	*)	-	-	-	-	*	-
en_1691.txt	0	12	a	DT	(NP(NP*	-	-	-	-	*	-
en_1691.txt	0	13	concern	NN	*)	-	-	-	-	*	-
en_1691.txt	0	14	with	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	15	hepB	NN	(NP*)))))))))))	-	-	-	-	*	-
en_1691.txt	0	16	,	,	*	-	-	-	-	*	-
en_1691.txt	0	17	and	CC	*	-	-	-	-	*	-
en_1691.txt	0	18	it	PRP	(S(NP*)	-	-	-	-	*	(14)
en_1691.txt	0	19	is	VBZ	(VP*	-	-	-	-	*	-
en_1691.txt	0	20	unlikely	JJ	(ADJP*	-	-	-	-	*	-
en_1691.txt	0	21	to	TO	(S(VP*	-	-	-	-	*	-
en_1691.txt	0	22	occur	VB	(VP*	-	-	-	-	*	-
en_1691.txt	0	23	with	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	24	HPV	NNP	(NP*))))))))	-	-	-	-	*	(6)
en_1691.txt	0	25	.	.	*))	-	-	-	-	*	-

en_1691.txt	0	0	Since	IN	(TOP(S(PP*	-	-	-	-	*	-
en_1691.txt	0	1	its	PRP$	(NP(NP*	-	-	-	-	*	(14)
en_1691.txt	0	2	launch	NN	*)	-	-	-	-	*	-
en_1691.txt	0	3	in	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	4	2000	CD	(NP*))))	-	-	-	-	*	-
en_1691.txt	0	5	,	,	*	-	-	-	-	*	-
en_1691.txt	0	6	the	DT	(NP*	-	-	-	-	*	(13
en_1691.txt	0	7	GAVI	NNP	*	-	-	-	-	*	-
en_1691.txt	0	8	Alliance	NNP	*)	-	-	-	-	*	13)
en_1691.txt	0	9	has	VBZ	(VP*	-	-	-	-	*	-
en_1691.txt	0	10	sought	VBN	(VP*	-	-	-	-	*	-
en_1691.txt	0	11	to	TO	(S(VP*	-	-	-	-	*	-
en_1691.txt	0	12	increase	VB	(VP*	-	-	-	-	*	-
en_1691.txt	0	13	access	NN	(NP(NP*)	-	-	-	-	*	-
en_1691.txt	0	14	to	TO	(PP*	-	-	-	-	*	-
en_1691.txt	0	15	life-saving	JJ	(NP*	-	-	-	-	*	-
en_1691.txt	0	16	vaccines	NNS	*)))	-	-	-	-	*	-
en_1691.txt	0	17	for	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	18	the	DT	(NP(NP*	-	-	-	-	*	(4
en_1691.txt	0	19	world	NN	*	-	-	-	-	*	-
en_1691.txt	0	20	'	POS	*)	-	-	-	-	*	4)
en_1691.txt	0	21	s	JJ	*	-	-	-	-	*	-
en_1691.txt	0	22	poorest	JJS	*	-	-	-	-	*	-
en_1691.txt	0	23	children	NNS	*)))))))	-	-	-	-	*	-
en_1691.txt	0	24	.	.	*))	-	-	-	-	*	-

en_1691.txt	0	0	In	IN	(TOP(S(PP*	-	-	-	-	*	-
en_1691.txt	0	1	partnership	NN	(NP(NP*)	-	-	-	-	*	-
en_1691.txt	0	2	with	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	3	the	DT	(NP(NP*	-	-	-	-	*	-
en_1691.txt	0	4	World	NNP	*	-	-	-	-	*	-
en_1691.txt	0	5	Bank	NNP	*)	-	-	-	-	*	-
en_1691.txt	0	6	,	,	*	-	-	-	-	*	-
en_1691.txt	0	7	the	DT	(NP*	-	-	-	-	*	(12
en_1691.txt	0	8	WHO	NNP	*)	-	-	-	-	*	12)
en_1691.txt	0	9	,	,	*	-	-	-	-	*	-
en_1691.txt	0	10	UNICEF	NNP	(NP*)	-	-	-	-	*	(15)
en_1691.txt	0	11	,	,	*	-	-	-	-	*	-
en_1691.txt	0	12	and	CC	*	-	-	-	-	*	-
en_1691.txt	0	13	the	DT	(NP*	-	-	-	-	*	-
en_1691.txt	0	14	Bill	NNP	*	-	-	-	-	*	-
en_1691.txt	0	15	&	CC	*	-	-	-	-	*	-
en_1691.txt	0	16	Melinda	NNP	*	-	-	-	-	*	-
en_1691.txt	0	17	Gates	NNP	*	-	-	-	-	*	-
en_1691.txt	0	18	Foundation	NNP	*)))))	-	-	-	-	*	-
en_1691.txt	0	19	,	,	*	-	-	-	-	*	-
en_1691.txt	0	20	it	PRP	(NP*)	-	-	-	-	*	(15)
en_1691.txt	0	21	has	VBZ	(VP*	-	-	-	-	*	-
en_1691.txt	0	22	used	VBN	(VP*	-	-	-	-	*	-
en_1691.txt	0	23	innovative	JJ	(NP*	-	-	-	-	*	-
en_1691.txt	0	24	financing	NN	*	-	-	-	-	*	-
en_1691.txt	0	25	tools	NNS	*)	-	-	-	-	*	-
en_1691.txt	0	26	to	TO	(S(VP*	-	-	-	-	*	-
en_1691.txt	0	27	raise	VB	(VP*	-	-	-	-	*	-
en_1691.txt	0	28	funds	NNS	(NP*)	-	-	-	-	*	-
en_1691.txt	0	29	for	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	30	global	JJ	(NP*	-	-	-	-	*	-
en_1691.txt	0	31	immunization	NN	*	-	-	-	-	*	-
en_1691.txt	0	32	programs	NNS	*)))))	-	-	-	-	*	-
en_1691.txt	0	33	,	,	*	-	-	-	-	*	-
en_1691.txt	0	34	while	IN	(SBAR*	-	-	-	-	*	-
en_1691.txt	0	35	working	VBG	(S(VP*	-	-	-	-	*	-
en_1691.txt	0	36	with	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	37	industry	NN	(NP*))	-	-	-	-	*	-
en_1691.txt	0	38	to	TO	(S(VP*	-	-	-	-	*	-
en_1691.txt	0	39	lower	VB	(VP*	-	-	-	-	*	-
en_1691.txt	0	40	the	DT	(NP(NP*	-	-	-	-	*	-
en_1691.txt	0	41	prices	NNS	*)	-	-	-	-	*	-
en_1691.txt	0	42	of	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	43	vaccines	NNS	(NP*)))))))))))	-	-	-	-	*	-
en_1691.txt	0	44	.	.	*))	-	-	-	-	*	-

en_1691.txt	0	0	By	IN	(TOP(S(PP*	-	-	-	-	*	-
en_1691.txt	0	1	including	VBG	(S(VP*	-	-	-	-	*	-
en_1691.txt	0	2	the	DT	(NP*	-	-	-	-	*	(16
en_1691.txt	0	3	hepB	JJ	*	-	-	-	-	*	-
en_1691.txt	0	4	vaccine	NN	*)	-	-	-	-	*	16)
en_1691.txt	0	5	as	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	6	part	NN	(NP(NP*)	-	-	-	-	*	-
en_1691.txt	0	7	of	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	8	a	DT	(NP*	-	-	-	-	*	-
en_1691.txt	0	9	pentavalent	JJ	*	-	-	-	-	*	-
en_1691.txt	0	10	-LRB-	-LRB-	(PRN*	-	-	-	-	*	-
en_1691.txt	0	11	five	CD	(NP(NP*)	-	-	-	-	*	-
en_1691.txt	0	12	in	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	13	one	CD	(NP*)))	-	-	-	-	*	-
en_1691.txt	0	14	-RRB-	-RRB-	*)	-	-	-	-	*	-
en_1691.txt	0	15	vaccine	NN	*)))))))	-	-	-	-	*	-
en_1691.txt	0	16	,	,	*	-	-	-	-	*	-
en_1691.txt	0	17	the	DT	(NP*	-	-	-	-	*	(13
en_1691.txt	0	18	Alliance	NNP	*)	-	-	-	-	*	13)
en_1691.txt	0	19	has	VBZ	(VP*	-	-	-	-	*	-
en_1691.txt	0	20	already	RB	(ADVP*)	-	-	-	-	*	-
en_1691.txt	0	21	facilitated	VBN	(VP*	-	-	-	-	*	-
en_1691.txt	0	22	its	PRP$	(NP(NP*	-	-	-	-	*	(13)
en_1691.txt	0	23	delivery	NN	*)	-	-	-	-	*	-
en_1691.txt	0	24	to	TO	(PP*	-	-	-	-	*	-
en_1691.txt	0	25	children	NNS	(NP*)))	-	-	-	-	*	-
en_1691.txt	0	26	in	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	27	70	CD	(NP*	-	-	-	-	*	-
en_1691.txt	0	28	countries	NNS	*))	-	-	-	-	*	-
en_1691.txt	0	29	as	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	30	part	NN	(NP(NP*)	-	-	-	-	*	-
en_1691.txt	0	31	of	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	32	routine	JJ	(NP*	-	-	-	-	*	-
en_1691.txt	0	33	immunizations	NNS	*))))))	-	-	-	-	*	-
en_1691.txt	0	34	.	.	*))	-	-	-	-	*	-

en_1691.txt	0	0	The	DT	(TOP(S(S(NP*	-	-	-	-	*	(13
en_1691.txt	0	1	Alliance	NNP	*)	-	-	-	-	*	13)
en_1691.txt	0	2	is	VBZ	(VP*	-	-	-	-	*	-
en_1691.txt	0	3	now	RB	(ADVP*)	-	-	-	-	*	-
en_1691.txt	0	4	working	VBG	(VP*	-	-	-	-	*	-
en_1691.txt	0	5	to	TO	(S(VP*	-	-	-	-	*	-
en_1691.txt	0	6	make	VB	(VP*	-	-	-	-	*	-
en_1691.txt	0	7	the	DT	(S(NP*	-	-	-	-	*	(16
en_1691.txt	0	8	HPV	NNP	*	-	-	-	-	*	-
en_1691.txt	0	9	vaccine	NN	*)	-	-	-	-	*	16)
en_1691.txt	0	10	available	JJ	(ADJP*	-	-	-	-	*	-
en_1691.txt	0	11	to	TO	(PP*	-	-	-	-	*	-
en_1691.txt	0	12	more	JJR	(NP(NP(NP(QP*	-	-	-	-	*	-
en_1691.txt	0	13	than	IN	*	-	-	-	-	*	-
en_1691.txt	0	14	30	CD	*	-	-	-	-	*	-
en_1691.txt	0	15	million	CD	*))	-	-	-	-	*	-
en_1691.txt	0	16	of	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	17	the	DT	(NP(NP(NP*	-	-	-	-	*	(4
en_1691.txt	0	18	world	NN	*	-	-	-	-	*	-
en_1691.txt	0	19	'	POS	*)	-	-	-	-	*	4)
en_1691.txt	0	20	s	JJ	*	-	-	-	-	*	-
en_1691.txt	0	21	poorest	JJS	*	-	-	-	-	*	-
en_1691.txt	0	22	women	NNS	*	-	-	-	-	*	-
en_1691.txt	0	23	and	CC	*	-	-	-	-	*	-
en_1691.txt	0	24	girls	NNS	*)	-	-	-	-	*	-
en_1691.txt	0	25	by	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	26	2020	CD	(NP*)))))	-	-	-	-	*	-
en_1691.txt	0	27	;	:	*	-	-	-	-	*	-
en_1691.txt	0	28	as	IN	*	-	-	-	-	*	-
en_1691.txt	0	29	part	NN	(NP(NP*)	-	-	-	-	*	-
en_1691.txt	0	30	of	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	31	this	DT	(NP*	-	-	-	-	*	-
en_1691.txt	0	32	effort	NN	*)))))))))))))	-	-	-	-	*	-
en_1691.txt	0	33	,	,	*	-	-	-	-	*	-
en_1691.txt	0	34	and	CC	*	-	-	-	-	*	-
en_1691.txt	0	35	coinciding	VBG	(S(S(VP*	-	-	-	-	*	-
en_1691.txt	0	36	with	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	37	World	NNP	(NP*	-	-	-	-	*	(1
en_1691.txt	0	38	Cancer	NNP	*	-	-	-	-	*	-
en_1691.txt	0	39	Day	NNP	*))))	-	-	-	-	*	1)
en_1691.txt	0	40	,	,	*	-	-	-	-	*	-
en_1691.txt	0	41	it	PRP	(NP*)	-	-	-	-	*	(13)
en_1691.txt	0	42	has	VBZ	(VP*	-	-	-	-	*	-
en_1691.txt	0	43	launched	VBN	(VP*	-	-	-	-	*	-
en_1691.txt	0	44	demonstration	NN	(NP*	-	-	-	-	*	-
en_1691.txt	0	45	programs	NNS	*)	-	-	-	-	*	-
en_1691.txt	0	46	in	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	47	eight	CD	(NP*	-	-	-	-	*	(17
en_1691.txt	0	48	developing	JJ	*	-	-	-	-	*	-
en_1691.txt	0	49	countries	NNS	*)))))	-	-	-	-	*	17)
en_1691.txt	0	50	.	.	*))	-	-	-	-	*	-

en_1691.txt	0	0	A	DT	(TOP(S(NP(NP*	-	-	-	-	*	-
en_1691.txt	0	1	growing	VBG	*	-	-	-	-	*	-
en_1691.txt	0	2	body	NN	*)	-	-	-	-	*	-
en_1691.txt	0	3	of	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	4	evidence	NN	(NP*)))	-	-	-	-	*	-
en_1691.txt	0	5	shows	VBZ	(VP*	-	-	-	-	*	-
en_1691.txt	0	6	that	IN	(SBAR*	-	-	-	-	*	-
en_1691.txt	0	7	vaccines	NNS	(S(NP(NP*	-	-	-	-	*	(18
en_1691.txt	0	8	'	POS	*)	-	-	-	-	*	18)
en_1691.txt	0	9	benefits	NNS	*)	-	-	-	-	*	-
en_1691.txt	0	10	extend	VBP	(VP*	-	-	-	-	*	-
en_1691.txt	0	11	beyond	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	12	preventing	VBG	(NP*	-	-	-	-	*	-
en_1691.txt	0	13	illness	NN	*	-	-	-	-	*	-
en_1691.txt	0	14	and	CC	*	-	-	-	-	*	-
en_1691.txt	0	15	death	NN	*))))))	-	-	-	-	*	-
en_1691.txt	0	16	.	.	*))	-	-	-	-	*	-

en_1691.txt	0	0	They	PRP	(TOP(S(S(NP*)	-	-	-	-	*	(18)
en_1691.txt	0	1	have	VBP	(VP*	-	-	-	-	*	-
en_1691.txt	0	2	also	RB	(ADVP*)	-	-	-	-	*	-
en_1691.txt	0	3	been	VBN	(VP*	-	-	-	-	*	-
en_1691.txt	0	4	found	VBN	(VP*	-	-	-	-	*	-
en_1691.txt	0	5	to	TO	(S(VP*	-	-	-	-	*	-
en_1691.txt	0	6	aid	VB	(VP*	-	-	-	-	*	-
en_1691.txt	0	7	infants	NNS	(NP*))))))))	-	-	-	-	*	-
en_1691.txt	0	8	'	:	*	-	-	-	-	*	-
en_1691.txt	0	9	cognitive	JJ	(S(NP*	-	-	-	-	*	-
en_1691.txt	0	10	development	NN	*	-	-	-	-	*	-
en_1691.txt	0	11	and	CC	*	-	-	-	-	*	-
en_1691.txt	0	12	children	NNS	*	-	-	-	-	*	-
en_1691.txt	0	13	'	POS	*)	-	-	-	-	*	-
en_1691.txt	0	14	s	VBZ	(VP*	-	-	-	-	*	-
en_1691.txt	0	15	educational	JJ	(NP*	-	-	-	-	*	-
en_1691.txt	0	16	attainment	NN	*)	-	-	-	-	*	-
en_1691.txt	0	17	,	,	*	-	-	-	-	*	-
en_1691.txt	0	18	thus	RB	(S(ADVP*)	-	-	-	-	*	-
en_1691.txt	0	19	boosting	VBG	(VP*	-	-	-	-	*	-
en_1691.txt	0	20	countries	NNS	(NP(NP*	-	-	-	-	*	(17
en_1691.txt	0	21	'	POS	*)	-	-	-	-	*	17)
en_1691.txt	0	22	economic-growth	JJ	*	-	-	-	-	*	-
en_1691.txt	0	23	potential	NN	*)))))	-	-	-	-	*	-
en_1691.txt	0	24	.	.	*))	-	-	-	-	*	-

en_1691.txt	0	0	In	IN	(TOP(S(PP*	-	-	-	-	*	-
en_1691.txt	0	1	the	DT	(NP(NP*	-	-	-	-	*	-
en_1691.txt	0	2	fight	NN	*)	-	-	-	-	*	-
en_1691.txt	0	3	against	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	4	cancer	NN	(NP*))))	-	-	-	-	*	-
en_1691.txt	0	5	,	,	*	-	-	-	-	*	-
en_1691.txt	0	6	medical	JJ	(NP*	-	-	-	-	*	-
en_1691.txt	0	7	advances	NNS	*)	-	-	-	-	*	-
en_1691.txt	0	8	can	MD	(VP*	-	-	-	-	*	-
en_1691.txt	0	9	shave	VB	(VP*	-	-	-	-	*	-
en_1691.txt	0	10	precious	JJ	(NP*	-	-	-	-	*	-
en_1691.txt	0	11	percentage	NN	*	-	-	-	-	*	-
en_1691.txt	0	12	points	NNS	*)	-	-	-	-	*	-
en_1691.txt	0	13	off	RP	(PRT*)	-	-	-	-	*	-
en_1691.txt	0	14	of	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	15	mortality	NN	(NP(NP*	-	-	-	-	*	-
en_1691.txt	0	16	rates	NNS	*)	-	-	-	-	*	-
en_1691.txt	0	17	,	,	*	-	-	-	-	*	-
en_1691.txt	0	18	which	WDT	(SBAR(WHNP*)	-	-	-	-	*	-
en_1691.txt	0	19	implies	VBZ	(S(VP*	-	-	-	-	*	-
en_1691.txt	0	20	that	IN	(SBAR*	-	-	-	-	*	-
en_1691.txt	0	21	improved	JJ	(S(NP(NP*	-	-	-	-	*	-
en_1691.txt	0	22	access	NN	*)	-	-	-	-	*	-
en_1691.txt	0	23	to	TO	(PP*	-	-	-	-	*	-
en_1691.txt	0	24	vaccines	NNS	(NP*)))	-	-	-	-	*	-
en_1691.txt	0	25	can	MD	(VP*	-	-	-	-	*	-
en_1691.txt	0	26	have	VB	(VP*	-	-	-	-	*	-
en_1691.txt	0	27	a	DT	(NP*	-	-	-	-	*	-
en_1691.txt	0	28	massive	JJ	*	-	-	-	-	*	-
en_1691.txt	0	29	impact	NN	*)	-	-	-	-	*	-
en_1691.txt	0	30	,	,	*	-	-	-	-	*	-
en_1691.txt	0	31	slashing	VBG	(S(VP*	-	-	-	-	*	-
en_1691.txt	0	32	the	DT	(NP(NP*	-	-	-	-	*	-
en_1691.txt	0	33	number	NN	*)	-	-	-	-	*	-
en_1691.txt	0	34	of	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	35	future	JJ	(NP*	-	-	-	-	*	-
en_1691.txt	0	36	cases	NNS	*))	-	-	-	-	*	-
en_1691.txt	0	37	in	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	38	developing	VBG	(NP*	-	-	-	-	*	-
en_1691.txt	0	39	countries	NNS	*)))	-	-	-	-	*	-
en_1691.txt	0	40	for	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	41	just	RB	(NP(NP*	-	-	-	-	*	-
en_1691.txt	0	42	a	DT	*	-	-	-	-	*	-
en_1691.txt	0	43	few	JJ	*	-	-	-	-	*	-
en_1691.txt	0	44	dollars	NNS	*)	-	-	-	-	*	-
en_1691.txt	0	45	per	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	46	dose	NN	(NP*)))))))))))))))))	-	-	-	-	*	-
en_1691.txt	0	47	.	.	*))	-	-	-	-	*	-

en_1691.txt	0	0	People	NNS	(TOP(S(NP(NP*)	-	-	-	-	*	-
en_1691.txt	0	1	in	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	2	rich	JJ	(NP*	-	-	-	-	*	-
en_1691.txt	0	3	countries	NNS	*)))	-	-	-	-	*	-
en_1691.txt	0	4	are	VBP	(VP*	-	-	-	-	*	-
en_1691.txt	0	5	undoubtedly	RB	(ADJP(ADJP*	-	-	-	-	*	-
en_1691.txt	0	6	familiar	JJ	*	-	-	-	-	*	-
en_1691.txt	0	7	with	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	8	the	DT	(NP*	-	-	-	-	*	-
en_1691.txt	0	9	maxim	NN	*)))	-	-	-	-	*	-
en_1691.txt	0	10	that	IN	(SBAR*	-	-	-	-	*	-
en_1691.txt	0	11	prevention	NN	(S(NP*)	-	-	-	-	*	-
en_1691.txt	0	12	is	VBZ	(VP*	-	-	-	-	*	-
en_1691.txt	0	13	better	JJR	(ADJP(ADJP*)	-	-	-	-	*	-
en_1691.txt	0	14	than	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	15	cure	NN	(NP*))))))))	-	-	-	-	*	-
en_1691.txt	0	16	.	.	*))	-	-	-	-	*	-

en_1691.txt	0	0	But	CC	(TOP(S*	-	-	-	-	*	-
en_1691.txt	0	1	,	,	*	-	-	-	-	*	-
en_1691.txt	0	2	given	VBN	(PP*	-	-	-	-	*	-
en_1691.txt	0	3	the	DT	(NP(NP*	-	-	-	-	*	-
en_1691.txt	0	4	ready	JJ	*	-	-	-	-	*	-
en_1691.txt	0	5	availability	NN	*)	-	-	-	-	*	-
en_1691.txt	0	6	of	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	7	vaccines	NNS	(NP(NP*)	-	-	-	-	*	-
en_1691.txt	0	8	in	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	9	developed	VBN	(NP*	-	-	-	-	*	-
en_1691.txt	0	10	countries	NNS	*))))))	-	-	-	-	*	-
en_1691.txt	0	11	,	,	*	-	-	-	-	*	-
en_1691.txt	0	12	the	DT	(NP(NP*	-	-	-	-	*	-
en_1691.txt	0	13	focus	NN	*)	-	-	-	-	*	-
en_1691.txt	0	14	of	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	15	prevention	NN	(NP*	-	-	-	-	*	-
en_1691.txt	0	16	efforts	NNS	*)))	-	-	-	-	*	-
en_1691.txt	0	17	has	VBZ	(VP*	-	-	-	-	*	-
en_1691.txt	0	18	shifted	VBN	(VP*	-	-	-	-	*	-
en_1691.txt	0	19	to	TO	(PP*	-	-	-	-	*	-
en_1691.txt	0	20	changing	VBG	(S(VP*	-	-	-	-	*	-
en_1691.txt	0	21	cancer-causing	JJ	(NP*	-	-	-	-	*	-
en_1691.txt	0	22	lifestyles	NNS	*))))))	-	-	-	-	*	-
en_1691.txt	0	23	.	.	*))	-	-	-	-	*	-

en_1691.txt	0	0	Meanwhile	RB	(TOP(S(ADVP*)	-	-	-	-	*	-
en_1691.txt	0	1	,	,	*	-	-	-	-	*	-
en_1691.txt	0	2	people	NNS	(NP(NP*)	-	-	-	-	*	-
en_1691.txt	0	3	in	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	4	developing	VBG	(NP*	-	-	-	-	*	-
en_1691.txt	0	5	countries	NNS	*)))	-	-	-	-	*	-
en_1691.txt	0	6	lack	VBP	(VP*	-	-	-	-	*	-
en_1691.txt	0	7	access	NN	(NP(NP*)	-	-	-	-	*	-
en_1691.txt	0	8	to	TO	(PP*	-	-	-	-	*	-
en_1691.txt	0	9	simple	JJ	(NP(NP(ADJP*	-	-	-	-	*	-
en_1691.txt	0	10	and	CC	*	-	-	-	-	*	-
en_1691.txt	0	11	effective	JJ	*)	-	-	-	-	*	-
en_1691.txt	0	12	tools	NNS	*)	-	-	-	-	*	-
en_1691.txt	0	13	for	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	14	preventing	VBG	(S(VP*	-	-	-	-	*	-
en_1691.txt	0	15	several	JJ	(NP(NP*)	-	-	-	-	*	-
en_1691.txt	0	16	of	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	17	the	DT	(NP*	-	-	-	-	*	-
en_1691.txt	0	18	most	RBS	(ADJP*	-	-	-	-	*	-
en_1691.txt	0	19	common	JJ	*)	-	-	-	-	*	-
en_1691.txt	0	20	cancers	NNS	*))))))))))	-	-	-	-	*	-
en_1691.txt	0	21	.	.	*))	-	-	-	-	*	-

en_1691.txt	0	0	Improving	NN	(TOP(S(NP(NP*	-	-	-	-	*	-
en_1691.txt	0	1	access	NN	*)	-	-	-	-	*	-
en_1691.txt	0	2	to	TO	(PP*	-	-	-	-	*	-
en_1691.txt	0	3	vaccines	NNS	(NP*)))	-	-	-	-	*	-
en_1691.txt	0	4	is	VBZ	(VP*	-	-	-	-	*	-
en_1691.txt	0	5	crucial	JJ	(ADJP*	-	-	-	-	*	-
en_1691.txt	0	6	to	TO	(PP*	-	-	-	-	*	-
en_1691.txt	0	7	addressing	VBG	(S(VP(VP*	-	-	-	-	*	-
en_1691.txt	0	8	this	DT	(NP*	-	-	-	-	*	-
en_1691.txt	0	9	global	JJ	*	-	-	-	-	*	-
en_1691.txt	0	10	inequity	NN	*))	-	-	-	-	*	-
en_1691.txt	0	11	and	CC	*	-	-	-	-	*	-
en_1691.txt	0	12	reducing	VBG	(VP*	-	-	-	-	*	-
en_1691.txt	0	13	the	DT	(NP*	-	-	-	-	*	-
en_1691.txt	0	14	widening	NN	*	-	-	-	-	*	-
en_1691.txt	0	15	gap	NN	*)	-	-	-	-	*	-
en_1691.txt	0	16	between	IN	(PP*	-	-	-	-	*	-
en_1691.txt	0	17	rich	JJ	(ADJP*	-	-	-	-	*	-
en_1691.txt	0	18	and	CC	*	-	-	-	-	*	-
en_1691.txt	0	19	poor	JJ	*))))))))	-	-	-	-	*	-
en_1691.txt	0	20	.	.	*))	-	-	-	-	*	-

en_1691.txt	0	0	This	DT	(TOP(S(NP*)	-	-	-	-	*	-
en_1691.txt	0	1	requires	VBZ	(VP*	-	-	-	-	*	-
en_1691.txt	0	2	,	,	*	-	-	-	-	*	-
en_1691.txt	0	3	first	RB	(ADVP*	-	-	-	-	*	-
en_1691.txt	0	4	and	CC	*	-	-	-	-	*	-
en_1691.txt	0	5	foremost	RB	*)	-	-	-	-	*	-
en_1691.txt	0	6	,	,	*	-	-	-	-	*	-
en_1691.txt	0	7	dispelling	VBG	(S(VP*	-	-	-	-	*	-
en_1691.txt	0	8	the	DT	(NP*	-	-	-	-	*	-
en_1691.txt	0	9	myth	NN	*	-	-	-	-	*	-
en_1691.txt	0	10	that	IN	(SBAR*	-	-	-	-	*	-
en_1691.txt	0	11	one	CD	(S(NP*	-	-	-	-	*	-
en_1691.txt	0	12	cannot	NN	*)	-	-	-	-	*	-
en_1691.txt	0	13	``	``	(VP*	-	-	-	-	*	-
en_1691.txt	0	14	catch	VB	*	-	-	-	-	*	-
en_1691.txt	0	15	''	''	*	-	-	-	-	*	-
en_1691.txt	0	16	cancer	NN	(NP*))))))))	-	-	-	-	*	-
en_1691.txt	0	17	.	.	*))	-	-	-	-	*	-

#end document
